
Bristol-Myers (BMY) Stock Forecast & Price Target
Bristol-Myers (BMY) Analyst Ratings
Bulls say
Bristol-Myers Squibb is projected to see steady growth through 2028, exceeding consensus estimates in both total revenue and EPS. With a strong pipeline in immuno-oncology and promising results from recent drug trials, BMY has increased conviction in its transformative potential and has overcome previous overhangs. In-depth interviews with experts also suggest significant market potential for its CELMoD drugs, and recent validation of the Factor XIa class in SSP further supports the company's potential for success. Overall, with strong management guidance and a solid dividend, BMY is a buy for investors looking for potential high-reward Ph 3 catalysts.
Bears say
Bristol-Myers Squibb is facing potential downside risks due to the possibility of competitors obtaining better results in their rare cardiovascular, inflammation, and oncology treatments, as well as the potential failure of mid- or late-stage pipeline programs. Furthermore, regulatory delays and macro/policy-related risks could also impact the company's performance. Given the company's high dependence on the US market and its focus on immuno-oncology, any negative outcomes in these areas could significantly impact Bristol-Myers Squibb's financials and overall outlook.
This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.
Bristol-Myers (BMY) Analyst Forecast & Price Prediction
Start investing in Bristol-Myers (BMY)
Order type
Buy in
Order amount
Est. shares
0 shares